This roundtable series debates using newer JAK inhibitors as therapy for patients with myelofibrosis, considering the efficacy and safety profiles of the drugs, as discussed by participants at virtual live events.
Goals of Managing Cytopenic Myelofibrosis in Younger Patients
August 29th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, and participants discussed the role of JAK inhibitors in managing myelofibrosis particularly in younger patients who may receive allogeneic stem cell transplant. This is the first of 2 articles based on this event.
Challenges of Interpreting JAK Inhibitor Data for Real-World Myelofibrosis Care
March 4th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Bart Scott, MD, discussed the importance of overall survival data in JAK inhibitor trials and how to transition between agents. This is the second of 2 articles based on this event.